The Detection of SARS-CoV-2 Antibodies in an Exposed Human Population Is Biased by the Immunoassay Used: Implications in Serosurveillance.

Publication date: Nov 16, 2023

The presence of SARS-CoV-2 antibodies was examined over 7 months in a population of essential service workers exposed during the first epidemic wave in Madrid (Spain). Results obtained with different serological assays were compared. Firstly, serum samples obtained in April 2020 were analyzed using eleven SARS-CoV-2 antibody detection methods, including seven ELISAs, two CLIAs and two LFAs. While all of the ELISA tests and the Roche eCLIA method showed good performance, it was poorer for the Abbott CLIA and LFA tests. Sera from 115 workers with serologically positive results in April were collected 2 and 7 months after the first sampling and were analyzed using five of the tests previously assessed. The results showed that while some ELISA tests consistently detected the presence of anti-SARS-CoV-2 antibodies even 7 months after first detection, other methods, such as the Abbott CLIA test, showed an important reduction in sensitivity for these mature antibodies. The sensitivity increased after establishing new cut-off values, calculated taking into account both recent and old infections, suggesting that an adjustment of assay parameters may improve the detection of individuals exposed to the infection.

Open Access PDF

Concepts Keywords
Antibodies CLIA
April COVID-19
Performance ELISA
Poorer LFA
Spain SARS-CoV-2
serologic assays


Type Source Name
disease VO population
disease MESH infections
disease IDO assay
disease IDO infection
disease MESH COVID 19
drug DRUGBANK Coenzyme M
disease VO organization
disease VO volume
drug DRUGBANK Phosphate ion
drug DRUGBANK Immune Globulin Human
disease VO USA
drug DRUGBANK Saquinavir
drug DRUGBANK Tropicamide
disease VO immunized
disease VO vaccine
disease VO protocol
disease VO effective
disease VO efficient
disease VO time
disease VO vaccinated
disease VO device
disease VO efficiency
disease MESH Reinfection
disease VO inactivated vaccine
disease MESH Seroconversion
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO humoral immune response

Original Article

(Visited 1 times, 1 visits today)